Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer

TIESHI LIU1,2, XUEFENG QIU2, XIAOZHI ZHAO2, RONG YANG2, HUIBO LIAN2, FENG QU2, XIAOGONG LI2 and HONGQIAN GUO1,2

1Department of Urology, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210008; 2Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China

Received July 11, 2017; Accepted November 15, 2017

DOI: 10.3892/or.2017.6121

Correspondence to:
Dr Hongqian Guo, Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China
E-mail: dr_guohq@126.com

Key words: prostate cancer, SPARC, hypermethylation, biomarker

Abstract. Secreted protein acidic and rich in cysteine (SPARC) is a secreted matricellular glycoprotein and plays a key role in the development of many tissues and organ types. However, the role of SPARC in prostate cancer (PCa) is still controversial. The aim of the present study was to investigate the abnormalities in the expression of SPARC and its promoter hypermethylation in prostate cancers and in correlated clinicopathological profiles. We examined the hypermethylation of the SPARC promoter as a potential mechanism for suppressing SPARC in PCa. The clinicopathological correlation between SPARC and its promoter expression and the prognostic significance of the aberrantly expressed genes were evaluated to identify novel biomarkers of PCa. SPARC expression was decreased in PCa cell lines, which correlated with hypermethylation of the SPARC promoter. Treatment with the demethylating agent 5-Aza-Cdr restored SPARC expression. Seventy percent (145 of 207) of the primary tumors exhibited SPARC hypermethylation, while only 2.6% was found in normal prostate mucosa (n=38). In PCa cases, SPARC hypermethylation was correlated with a poorer prognosis (P=0.005; relative risk 2.659, 95% CI, 1.433-4.562). Our findings revealed potential diagnostic markers of PCa based on specific hypermethylated CpG sites and also provided new insights of SPARC as a novel biomarker and/or treatment modality for prostate cancer.

Introduction

Prostate cancer (PCa) is the most common malignancy in men, with an estimated 220,800 new cases and 27,540 deaths diagnosed in the USA in 2015 (1). Based on recent statistics, 161,360 newly diagnosed cases of PCa were reported. Among these cases, 26,730 American males were estimated to succumb to this disease in 2017, thus making PCa the most serious health problem among male patients (2). Radical prostatectomy and radiation therapy are the first choice treatments for PCa, while the prognosis is different according to the clinical stage, pathological grading and individual differences. Prostate-specific antigen (PSA), has been clinically and widely used for the diagnosis of PCa. However, PSA detection presents a high false-positive rate, thus failing to accurately assess the malignancy grade of the tumor. Therefore, it does not fully satisfy the clinician's need to determine the treatment modality for patients with PCa (3). Thus, more specific molecular markers for PCa diagnosis and treatment are urgently needed.

Recently, cumulative evidence has indicated that the initiation and progression of PCa results from the accumulation of genetic and epigenetic changes (4,5). DNA methylation occurs in the early process of PCa and it has the potential to be a novel marker with high detection sensitivity (6,7). Many genes, which play important roles in the pathogenesis and metastasis of PCa, are methylated. These methylated genes are potential biomarkers for the diagnosis and prognosis evaluation of PCa (8-10).

Secreted protein acidic and rich in cysteine (SPARC), also designated as osteonectin and BM-40, is expressed in tissues undergoing remodeling or repair and it also plays an important role in normal development. The level of SPARC expression depends on tumor types and the tumor cell environment. Different levels of SPARC expression have been reported in several tumors (11). Previous studies have revealed that SPARC can suppress PCa pathogenesis (12) and progression (13). Another study has demonstrated that exogenous SPARC inhibited the proliferation and migration of PCa cells (14). Furthermore, previous studies have revealed that SPARC hypermethylation was found in several cancers as well as PCAs (15-18).

The purpose of the present study was to investigate the status of SPARC hypermethylation in PCa cell lines and tumor tissues and to investigate its clinical relevance to prostate cancers, as well as in patient outcome. Furthermore, the possibility of SPARC hypermethylation as a predictive biomarker in PCa was affirmed.
Materials and methods

Cell culture. Five human PCa cell lines DU145, LNCaP, PC-3, NPC-3 and BPC-3, as well as the control prostate epithelial cell line (RWPE-1) were obtained from the Cancer Hospital of the Chinese Academy of Medical Sciences (Beijing, China). These cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (both were obtained from Invitrogen Life Technologies Inc., Rockville, MD, USA) and incubated in 5% CO₂ at 37°C.

Patient tissue specimens. A total of 207 surgically resected prostate samples were obtained from the Nanjing Drum Tower Hospital (Nanjing, China) from August 2005 to August 2007. The tissue samples were obtained and stored in liquid nitrogen immediately after being resected in the operating room. Informed consents were signed by all patients before surgery. All the clinical procedures were approved by the Medical Ethics Committee of the Nanjing Drum Tower Hospital. Two experienced radiologists (>10 years of experience in urogenital radiology) reviewed the magnetic resonance imaging (MRI) images together and concordantly identified the suspicious lesions using the Prostate Imaging Reporting and Data System (PI-RADS) version 2.

Quantitative real-time, reverse transcription-polymerase chain reaction (RT-PCR). Total RNA (1-2 µg) was reverse transcribed using a SuperScript Pre-Amplification kit (Invitrogen Life Technologies, Carlsbad, CA, USA). Fast SYBR-Green Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used for the qPCR assay. The primer sequences as well as annealing temperatures and cycle numbers were derived from published studies (19,20). The relative mRNA expression levels were normalized to the expression level of GAPDH using the 2⁻ΔΔCt method.

Immunoblot analysis. Total cell lysates were prepared and analyzed by immunoblot as aforementioned (19). The antibodies to SPARC (sc-25574, 1:800 dilution, rabbit polyclonal antibody; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and GAPDH (sc-69778, 1:800 dilution, mouse monoclonal antibody; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were used to detect SPARC and GAPDH, respectively. The labeling was detected with the Envision Plus Detection kit (Dako, Carpinteria, CA, USA) and incubated overnight in hematoxylin. The extent of immunolabeling of SPARC was scored as follows: 0%, negative; ≤10%, focal; and >10%, positive. The negative group consisted of cancer cells with no detectable (-) or only trace staining of SPARC immunoreactivity (+). The positive group consisted of cancer cells with moderate (++) or high levels (++++) of SPARC immunoreactivity. Two independent histopathologists were blindly assigned to review the slides and score the staining.

5-Aza-Cdr treatment. In total, five PCa cell lines (DU145, PC-3, NPC-3, BPC-3 and LNCAP) at 65% confluence were treated with the global genomic DNA demethylating agent 5-Aza-CdR. The cells were seeded in 6-well plates and incubated overnight in growth media. The normal growth media were replaced with growth media supplemented with 5 µM 5-Aza-CdR and were replenished daily for 5 days. At the conclusion of the treatment, the cells were harvested for RNA, genomic DNA and protein as previously described. At least three independent experiments were performed.

Cell proliferation assay. The cell proliferation assay was carried out as previously described (17). Two cell lines (DU145 and PC-3) were seeded into 48-well plates at a density of 1x10⁴ cells/well. These cells were cultured in growth media supplemented with 5 µM 5-Aza-CdR for 3 days. The cells were counted after treatment for 24, 48 and 72 h. A minimum of three independent experiments were performed. The cells in the normal growth media were treated as the controls.

Cell invasion and migration assays. CytoSelect 24-well cell migration and invasion assay kits (Cell Biolabs, Inc., San Diego, CA, USA) were used for the migration and invasion assays, according to the manufacturer’s instructions. The cells (1x10⁵ cells/ml serum-free media with 5 µM 5-Aza-CdR) were added to the upper compartment of the chamber and the lower chambers were filled with 750 µl media with 10% FBS. The cells were incubated for 24 h at 37°C and 5% CO₂, and then the non-migrated/non-invading cells on the upper side of the membrane were removed with a cotton swab. Migrated/invaded cells on the lower sides of the inserts were fixed with methanol and stained with 0.1% crystal violet. The number of cells was counted in five random fields using optical microscopy. A minimum of three independent experiments were performed.

Statistical analysis. SPSS version 18.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Continuous variables are shown as the mean ± standard deviation (SD) and the differences between groups were evaluated using unpaired Student’s t-tests. Statistical differences between groups were examined using Fisher’s exact test, χ² test and the Mann-Whitney test. Overall survival was evaluated using the Kaplan-Meier method and the log-rank test. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of SPARC and its hypermethylation analysis in PCa cell lines. We investigated the SPARC mRNA and protein expression in five prostate cancer cell lines and the control prostate epithelial cell line (RWPE-1). RT-PCR and immunoblotting revealed that SPARC was undetectable in the DU145 cell line and exhibited a low expression in the other four cancer cell lines (PC-3, NPC-3, BPC-3 and LNCAP; Fig. 1A). The expression levels of SPARC mRNA and protein in the RWPE-1 cell line were higher than in the PCa cell lines (Fig. 2A and B). Hypermethylation of the SPARC promoter was found in all five (5 out of 5, 100%) prostate cancer cell lines (Fig. 1B). SPARC mRNA expression and hypermethylation of SPARC could not be detected in the DU145 cell line, but both were clearly exhibited in the other four cell lines. These results are similar to the data previously described in PCa cell lines (15).

Rescue of SPARC expression by 5-Aza-Cdr treatment. In order to confirm that the hypermethylation of the SPARC gene results in the loss of the SPARC protein expression, the prostate cells lines were cultured with 5-Aza-Cdr. The results indicated that the 5-Aza-Cdr treatment rescued SPARC mRNA and protein expression in the DU145 cell line where the expression of SPARC was lost. Furthermore, the demethylating agent increased the expression of SPARC mRNA and protein in the other four cancer cell lines (Figs. 1C and D and 2C and D).

Investigation of SPARC gene hypermethylation. We further analyzed the hypermethylation status of the SPARC gene in PCa with the primers (Fig. 3) used in MSP, designed to detect hypermethylation of several CpG islands in the DU145, PC-3, NPC-3, BPC-3 and LNCAP cell lines.

Immunohistochemical analysis of the SPARC expression in PCa tissues and non-cancerous mucosa. To explore the expression and location of SPARC in tumors, immuno-
taining was performed on PCa tissues and non-cancerous mucosa. We observed moderate (++) to strong (+++) SPARC expression in most stromal cells (80/108). In addition, we observed that the SPARC protein expression was closely associated with the degree of differentiation (Fig. 4). Weak and focal staining was also observed in the neoplastic epithelium (28, 25.9%). In the remaining cases (80, 74.1%), the neoplastic cells did not label for SPARC throughout the tumor.

5-Aza-Cdr inhibits cell proliferation, invasion and migration. As mentioned above, the hypermethylation of the SPARC promoter could be reversed following incubation with 5-Aza-Cdr, which also resulted in higher levels of SPARC mRNA and protein expression. To examine whether the alteration of SPARC levels in the PCa cells leads to changes in cell biological behaviors, we assessed cell proliferation, migration and invasion. The results indicated that 5-Aza-Cdr significantly decreased the proliferation, migration and invasion in the DU145 cell line (negative SPARC expression) compared to the PC-3 cell line (SPARC positive expression) (Fig. 5).

Correlation between SPARC hypermethylation and the clinicopathological parameters in PCa patients. We collected clinicopathological data from the patients and then analyzed the SPARC hypermethylation and the clinicopathological parameters in PCa patients. The results indicated hypermethylation of SPARC in prostate tumors (145 out of 207, 70%), prostate mucosae (1 out of 38, 2.6%) and negative hypermethylation of SPARC in peripheral blood lymphocytes from patients (0 out of 30, 0%) and healthy volunteers (0 out of 30, 0%) (Fig. 6). The SPARC hypermethylation in the tumor tissues was not significantly associated with age, however, it was significantly associated with lymph node metastasis (P<0.001), advanced stages (P<0.001), a higher PI-RADS score (P=0.009) and a higher Gleason score (P<0.001) (Table I).
The overall survival curve revealed that patients with SPARC hypermethylation had a significantly poorer prognosis than those without SPARC hypermethylation (P=0.003; log-rank test; Fig. 7), as well as for subgroups of patients at advanced stages (P=0.008), with higher PI-RADS score (3,4,5), higher Gleason score (8,9,10) (P=0.025) and lymph node metastasis (P=0.016). In a multivariate Cox proportional hazards model, hypermethylation of the SPARC promoter was an independent adverse prognostic factor [P=0.005; relative risk (RR) 2.659, 95% CI, 1.433-4.562], as well as stage (P=0.017; RR 1.984, 95% CI, 1.242-3.809), PI-RADS score (P=0.013, RR 3.781, 95% CI, 1.474-6.237), Gleason score (P=0.032; RR 3.545, 95% CI, 1.246-5.619) and lymph node metastasis (P=0.021; RR 1.715, 95% CI, 2.052-5.751) in cancer cases (Table I).

Figure 5. 5-Aza-Cdr treatment inhibits (A) proliferation, (B) migration and (C) invasion of DU145 (SPARC negative cell line) and PC-3 (SPARC positive cell line). *P<0.05. SPARC, secreted protein acidic and rich in cysteine.

Discussion

Prostate cancer is a heterogeneous malignancy with mostly unpredictable outcome. Currently, some clinicopathological features, such as PSA, Gleason score and clinical stages, are used to predict patient outcome in clinical practice. However, they fail to accurately distinguish aggressive tumors from non-aggressive ones (24). Multiple studies indicated that aberrant DNA methylation is a hallmark of prostate cancer and is associated with malignant initiation and progression and demonstrated that aberrant DNA methylation may possibly be a potential biomarker of PCa (25).

In the present study, we investigated the role of DNA hypermethylation in the expression of SPARC in prostate cancer cells and stromal fibroblasts. In addition, we investigated the
correlation between SPARC hypermethylation status with clinicopathological parameters, as well as patient outcome. 

Table I. Correlation of the promoter hypermethylation of the SPARC gene with the clinical parameters of PCa patients.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. (%) (N=207)</th>
<th>Hypermethylation (N=145)</th>
<th>Unmethylation (N=62)</th>
<th>P-value</th>
<th>P-value</th>
<th>Risk ratio</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥67</td>
<td>116 (56.0)</td>
<td>80 (69.0)</td>
<td>36 (31.0)</td>
<td>0.410b</td>
<td>0.808</td>
<td>1.539</td>
<td>0.682</td>
<td>1.620</td>
</tr>
<tr>
<td>&lt;67</td>
<td>91 (44.0)</td>
<td>65 (71.4)</td>
<td>26 (28.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI-RADS score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1, 2</td>
<td>17 (8.2)</td>
<td>7 (64.7)</td>
<td>10 (35.3)</td>
<td>0.009b</td>
<td>0.010</td>
<td>3.781</td>
<td>1.474</td>
<td>6.237</td>
</tr>
<tr>
<td>3, 4, 5</td>
<td>190 (91.8)</td>
<td>138 (70.5)</td>
<td>52 (29.5)</td>
<td>0.001b</td>
<td>0.008</td>
<td>1.984</td>
<td>1.242</td>
<td>3.809</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I, II</td>
<td>87 (42.2)</td>
<td>45 (51.7)</td>
<td>42 (48.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III, IV</td>
<td>120 (57.8)</td>
<td>100 (83.3)</td>
<td>20 (16.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>68 (32.9)</td>
<td>37 (54.4)</td>
<td>31 (45.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8, 9, 10</td>
<td>139 (67.1)</td>
<td>108 (77.7)</td>
<td>31 (22.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>95 (45.9)</td>
<td>52 (54.7)</td>
<td>43 (45.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>112 (54.1)</td>
<td>93 (83.0)</td>
<td>19 (17.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total SPARC methylation status</td>
<td>145 (70.0)</td>
<td>62 (30.0)</td>
<td></td>
<td>0.003</td>
<td></td>
<td>2.659</td>
<td>1.433</td>
<td>4.562</td>
</tr>
</tbody>
</table>

*Divided by median age of cancer cases. *Pearson’s χ² test. SPARC, secreted protein acidic and rich in cysteine; PCa, prostate cancer; PI-RADS, prostate imaging reporting and data system; CI, confidence interval.

Our results revealed that hypermethylation of the SPARC promoter was the primary mechanism of SPARC down-regulation. SPARC expression was frequently lost during the promoter hypermethylation but could be restored by 5-Aza-Cdr. In prostate cancer tissue, the change in the SPARC expression followed a similar pattern as in pancreatic cancer.
where higher levels of SPARC were observed in normal epithelial cells whereas SPARC was absent in the majority of pancreatic cancer tissues (26). It is known that SPARC plays important roles in the development of proliferation and migration with complex biological effects and it is cell- and tumor-type specific (27). The loss of SPARC gene expression was also associated with promoter hypermethylation and could be rescued using 5-Aza-Cdr (23).

In PCa, although SPARC was reported as a predominantly protumorigenic protein (28), several studies revealed that SPARC downregulated the proliferation and invasion of PCa cells (12-14), indicating that SPARC was capable of becoming a useful immunohistochemical biomarker of PCa.

Our MSP results revealed that hypermethylation of specific CpG sites occurred at a high frequency in PCa cell lines, which could be a potential diagnostic or predictive marker of this disease. It is possible that the presence of complete or partial SPARC hypermethylation in some of these pathologically ‘normal’-appearing epithelium may, in fact, represent an early epigenetic event in the adenocarcinoma sequence that predisposes patients to develop prostate cancers. The confirmation of this hypothesis will require a further prospective study.

According to our data, advanced stage, higher Gleason score (8,9,10), higher PI-RADS score (3,4,5) and lymph node metastasis/positive were all associated with a poor prognosis in PCa. We also found that SPARC gene hypermethylation was correlated with a poor prognosis in PCa patients, which indicated that SPARC hypermethylation was associated with malignant behaviors of PCa cells.

Survival analysis indicated that patients with hypermethylated SPARC in the serum had worse overall survival than patients without methylated SPARC. Furthermore, SPARC hypermethylation was an independent predictive biomarker of poorer overall survival in PCa.

Our results also demonstrated that the SPARC expression was notably lower in cancer epithelial cells than that in stromal cells and 5-Aza-Cdr suppressed the biological behaviors of the prostate cell lines with SPARC promoter hypermethylation. A previous study (29) indicated that this inhibition may be associated with tumor growth and that SPARC had an antiproliferative function by modulating the cell cycle regulatory proteins or growth factors.

These results revealed that SPARC hypermethylation in serum is an independent prognostic biomarker in PCa. Patients with methylated SPARC in serum have higher risk of death. Therefore, it is a useful strategy to detect hypermethylated SPARC by using MSP on biopsies, serum and prostate lavage. Furthermore, SPARC hypermethylation profiling may be useful in establishing the epigenotype of each tumor in order to detect potential differences in occurrence of metastasis, sensitivity to chemotheraphy and/or overall prognosis (28).

In conclusion, we demonstrated that SPARC expression was notably decreased in PCa mainly due to the hypermethylation of its promoter region. Furthermore, the downregulation of SPARC expression is necessary for the progression of PCa and the restored SPARC expression inhibited the proliferation, invasion and migration of prostate carcinoma cells. The hypermethylation of SPARC was closely associated with the prognosis of PCa. Therefore, the hypermethylation of SPARC presents a good predictive value for PCa survival.

Acknowledgements

The present study was supported by the National Nature Science Foundation of China (nos. 81602232, 81302542 and 81572519).

References

trends of stage II colorectal cancer patients relate to promoter 
methylation status of PCDH10, SPARC, and UCHL1. Mod Pathol 
Bachem M and Kornmann M: Inhibition of endogenous 
SPARC enhances pancreatic cancer cell growth: Modulation by 
20. Tanpure S, Boyineini J, Gnanamony M, Antony R, Fernández KS, 
Libes J, Lin J, Pinson D, Joseph PA and Gondi CS: SPARC over-
expression suppresses radiation-induced HSP27 and induces the 
collapse of mitochondrial Δψ in neuroblastoma cells. Oncol Lett 
21. Kordi-Tamandani DM, Moazeni-Roodi AK, Rigi-Ladiz MA, 
Hashemi M, Birjandian E and Torkamanzehi A: Promoter hyper-
methylation and expression profile of MGMT and CDH1 genes in 
22. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: 
Methylation-specific PCR: A novel PCR assay for methylation 
status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 
1996.
Desai N, Mok SC and Motamed K: Aberrant promoter methyl-
24. Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, 
Hypermethylation of the GABRE−miR−452−miR−224 promoter 
in prostate cancer predicts biochemical recurrence after radical 
25. Strand SH, Örntoft TF and Sorensen KD: Prognostic DNA 
methylation markers for prostate cancer. Int J Mol Sci 15: 
16544-16576, 2014.
and Gong Y: Methylation of the SPARC gene promoter and its 
27. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E 
and Llera AS: The role of the matricellular protein SPARC in 
the dynamic interaction between the tumor and the host. Cancer 
28. Jacob K, Webber M, Benayahu D and Kleinman HK: Osteonectin 
promotes prostate cancer cell migration and invasion: A possible 
mechanism for metastasis to bone. Cancer Res 59: 4453-4457, 
1999.
29. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK and Kim H: 
Frequent inactivation of SPARC by promoter hypermethylation 